Exploring fatigue in Marfan and hypermobile Ehlers-Danlos syndromes: an analytical cross-sectional study…, 2025, Udugampolage+

Discussion in ''Conditions related to ME/CFS' news and research' started by SNT Gatchaman, Jan 7, 2025.

Tags:
  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    6,218
    Location:
    Aotearoa New Zealand
    Exploring fatigue in Marfan and hypermobile Ehlers-Danlos syndromes: an analytical cross-sectional study in two Italian healthcare centres
    Nathasha Udugampolage; Jacopo Taurino; Alessandra Bassotti; Alessandro Pini; Rosario Caruso; Edward Callus; Arianna Magon; Gianluca Conte; Giada De Angeli; Giulia Paglione; Irene Baroni; Giuliana Trifirò

    OBJECTIVE
    This study investigates the prevalence and underlying factors of fatigue in individuals with Marfan syndrome (MFS) and hypermobile Ehlers-Danlos syndromes (hEDS), highlighting the necessity for focused research on this symptom within these patient populations.

    DESIGN
    Cross-sectional, multicentre study.

    SETTING
    Data were collected from participants diagnosed with MFS or hEDS across multiple healthcare centres.

    PARTICIPANTS
    The study enrolled 282 participants (127 with MFS and 155 with hEDS).

    PRIMARY AND SECONDARY OUTCOME MEASURES
    Fatigue was measured using the Fatigue Severity Scale (FSS). Additional assessments included the Patient Health Questionnaire-9 (PHQ-9) for depression and the Insomnia Severity Index (ISI) for sleep disturbances.

    RESULTS
    Participants with hEDS exhibited significantly higher median fatigue scores (FSS median=5.9, IQR=5.00–6.44) compared with the MFS group (FSS median=4.0, IQR=2.88–5.00). Significant predictors of fatigue included being female, having hEDS, participating in psychotherapy, and elevated scores on depression and insomnia scales. In the overall sample, hEDS significantly predicted fatigue (B=0.430, p=0.022), with depression and insomnia as strong influencers (PHQ-9: B=0.12, p<0.001; ISI: B=0.092, p<0.001). Notably, 80% of the hEDS group reported clinically relevant fatigue levels, compared with 31.5% in the MFS group. Daily persistence of fatigue was especially pronounced in hEDS, with 72.2% reporting everyday fatigue versus 25.2% in MFS. Temporal fatigue patterns also differed, with a more evenly distributed pattern throughout the day in hEDS, correlating with higher insomnia scores.

    CONCLUSIONS
    The results underscore the severe impact of fatigue on individuals with hEDS compared with those with MFS, suggesting the need for targeted, multidisciplinary management strategies to enhance quality of life.

    Trial registration number NCT05712564

    Link | PDF (BMJ Open) [Open Access]
     
  2. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    16,008
    Location:
    London, UK
    It all depends on how they define hEDS. In general, 95% of people diagnosed as hEDS probably do not have EDS. They have fatigue and someone has given them a diagnosis of hEDS (which in general has no monogenic marker for a specific diagnosis).
     

Share This Page